Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions

A method of providing relief from or alleviating symptoms of or delaying the progression of autoimmune disease in a patient in need of said provision of relief or alleviation of symptoms or delay of progression, the method comprising administering a therapeutically effective amount of at least one compound having the formula:

• wherein R1, R2, R3, R4, R5 and R6, independently of one another, are substituents selected from H, C1-C6 alkyl, OH, halogen, C5-C14 aryl, C6-C20 aralkyl, C1-C6 alkylthio, C1-C6 alkoxy, SH, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, CN, NO2, carboxy, carbalkoxy, carboxamido, alkylsulfonyl, alkylsulfonyloxy, aminosulfinyl, monoalkylaminosulfinyl, dialkylaminosulfinyl, aminosulfonyl, monoalkylaminosulfonyl, dialkylaminosulfonyl, alkylsulfonylamino, hydroxysulfonyloxy, alkoxysulfonyloxy, alkylsulfonyloxy, hydroxysulfonyl, alkoxysulfonyl, alkylsulfonylalkyl, aminosulfonylalkyl, monoalkylaminosulfonylalkyl, dialkyaminosulfonylalkyl, aminosulfinylalkyl, monoalkylaminosulfinylalkyl, dialkylaminosulfinylalkyl, said alkyl, alkenyl, alkynyl or cycloalkyl substituent being optionally substituted by at least one halogen, OH, SH, NH2, C1-C4 monoalkylamino, C1-C4 dialkylamino, COOH, CN, NO2, C1-C4 alkyl or C1-C4 alkoxy group, said aryl and aralkyl substituent being optionally substituted by at least one halogen, OH, SH, NH2, C1-C4 monoalkylamino, C1-C4 dialkylamino, COOH, CN, NO2, C1-C4 alkyl or C1-C4 alkoxy group;
• Ra, Rb and Rc, independently of one another, represent substituents selected from H, C1-C4 alkyl, phenyl or phenyl C1-C4 alkyl, said alkyl substituent, said phenyl substituent and said phenyl C1-C4 alkyl substituent being optionally substituted by at least one halogen, OH, SH, NH2, C1-C4 alkylmethylamino, C1-C4 dialkylamino, COOH, CN, NO2, C1-C4 alkyl or C1-C4 alkoxy group;
• m, n and k are independent integers from 0-4, except that m+n≠0;
• and the pharmaceutically acceptable salts of said compound.